Non-surgical treatment of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 9-10, 1997, Pages

  Lin, Deng Yn ^a   Lin, Shi Ming ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Treatment

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ACETIC ACID; ALCOHOL; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRAQUINONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; INTERFERON; MALEIC ACID; MENOGARIL; MITOXANTRONE; PICIBANIL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GAMMA INTERFERON; STYRENE; TAMOXIFEN; ZINOSTATIN;

ALOPECIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CONFERENCE PAPER; DRUG EFFICACY; GENE THERAPY; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MUCOSA INFLAMMATION; OUTCOMES RESEARCH; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SEPSIS;

EID: 0030867119     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00516.x     Document Type: Conference Paper

References (97)

1. Cook GC, Moosa B. Hepatocellular carcinoma: One of the world's most common malignancies. Am. J. Med. 1985; 233: 705-8.
2. Chen MF, Hwang TL, Jeng LB et al. Hepatic resection in 120 patients with hepatocellular carcinoma. Arch. Surg. 1989; 124: 1025-8.
3. Liaw YF, Tai DI, Chu CM et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: A prospective study. Gastroenterology 1986; 70: 263-7.
4. Yoshimi F, Nagao T, Inque S et al. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: Necessity for prospective randomized trial. Hepatology 1992; 16: 702-6.
5. Castells A, Bruix J, Bru C et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 1121-6.
6. Kotoh K, Sakai H, Sakamoto S et al. The effect of percutaneous ethanol injection therapy on small hepatocellular carcinoma is comparable to that of hepatectomy. Am. J. Gastroenterol. 1994; 89: 194-8.
7. Buscarini L, Di Stasi M, Buscarini E et al. Clinical presentation, diagnostic work-up and therapeutic choices in two consecutive series of patients with hepatocellular carcinoma. Oncology 1996; 53: 204-9.
8. Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann. Surg. 1994; 219: 236-47.
9. Ohto M, Yoshikawa M, Saito H, Ebara M, Sugiura N. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients. World J. Surg. 1995; 19: 42-6.
10. Paraskevopoulos JH. Management options for primary hepatocellular carcinoma. An overview. Acta Oncol. 1994; 33: 895-900.
11. Venook AP. Treatment of hepatocellular carcinoma: Too many options? J. Clin. Oncol. 1994; 12: 1323-34.
12. Brennan M, Taley R, San Diego E et al. Critical analysis of 594 cancer patients treated with 5-fluorouracil. In: Platner A, ed. Proceedings of the International Symposium on Chemotherapy of Cancer. New York: Elsevier, 1964; 118-19.
13. Zaniboni A, Simoncini E, Marpicati P, Marini G. Phase II study of 5-fluorouracil (5-FU) and high dose folic acid (HDFA) in hepatocellular carcinoma. Br. J. Cancer 1988; 57: 319.
14. Yoshino M, Okazaki N, Yoshida T et al. A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn. J. Clin. Oncol. 1989; 19: 120-2.
15. Ravy MJ, Omura GA, Bartolucci AA, Einhorn L, Kramer B, Davila E. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangioma: A Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 1986; 70: 311-12.
16. Lin DY, Liaw YF. Phase II clinical trial of elliptinium in advanced hepatocellular carcinoma. Hepatogastroenterology 1992; 39: 286-90.
17. Falkson G, Burger W. A phase II trial of vindesine in hepatocellular cancer. Oncology 1995; 52: 86-7.
18. Olweny C, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi S, Cohen H. Treatment of hepatocellular carcinoma with adriamycin: Preliminary communication. Cancer 1975; 36: 1250-7.
19. Olweny C, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi S. Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 1980; 46: 2717-22.
20. Sciarrino E, Simonetti R, LeMoli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma: Experience with 109 patients. Cancer 1985; 56: 2751-5.
21. Lai CL, Wu PC, Chan GCB, Los ASF, Lin HJ. Doxorubicin versus no anti-tumor therapy in inoperable hepatocellular carcinoma: A prospective randomized trial. Cancer 1988; 62: 479-83.
22. Falkson G, Lipsitz S, Borden E, Simon I, Haller D. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am. J. Clin. Oncol 1995; 18: 287-92.
23. Bassendine MF, Curtin NJ, Losse H, Harris AL, James OF. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB 3717: A phase II study. J. Hepatol. 1987; 4: 349-56.
24. Kennedy P, Lahane D, Smith F, Lane M. Oral fluorouracil therapy of hepatoma. Cancer 1977; 37: 1930-5.
25. Tokyo Liver Cancer Chemotherapy Study Group. Phase II study of co-administration of uracil and Tegafur (UFT) in hepatocellular carcinoma. Jpn. J. Clin. Oncol. 1985; 15: 559-62.
26. Cheng E, Chun H, Schiff C, Kemeny N, Sordillo P, Young C. Phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in patients with primary liver carcinoma. Proc. Am. Soc. Clin. Oncol. 1985; 4: 88.
27. Leveille-Webster CR, Arias IA. Establishment and serial quantification of intrahepatic xenografts on human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin. Cancer Res. 1996; 2: 695-706.
28. Ellis PA, Normal A, Hill A et al. Epirubicine, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumors. Eur. J. Cancer 1995; 31A: 1594-8.
29. Porta C, Moroni M, Nastasi G, Arcangeli G. 5-fluorouracil and D,L-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: Preliminary results of a phase II study. Oncology 1995; 52: 487-91.
30. Denda T, Saisho H, Yoshikawa M et al. Chemosensitivity test for repeated arterial infusion chemotherapy by-reservoir for unresectable hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1995; 10: 446-53.
31. Cerezo FJ, Tomas A, Donoso L et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J. Hepatol. 1994; 20: 702-6.
32. Manesis E, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial. Hepatology 1995; 21: 1535-42.
33. Castells A, Bruix J, Bru C et al. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-22.
34. Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR, Chen DS. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996; 77: 872-7.
35. Jiang SY, Shyu RS, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J. Hepatol. 1995; 23: 712-19.
36. Chao Y, Chan WK, Huang YS et al. Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 1996; 7: 635-9.
37. Sachs E, DiBisceglie AM, Dusheiko GM et al. Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: A pilot study. Br. J. Cancer 1985; 52: 105-9.
38. Nakamura K, Kubo A, Hosokawa S, Nagaike K, Hashimoto S. Effect of alpha-interferon on anti-alphafetoprotein-monoclonal-antibody targeting of hepatoma. Oncology 1993; 50: 35-40.
39. Shouval D, Adler R. Tumor site-directed therapy for hepatocellular carcinoma using monoclonal antibodies against hepatoma-associated antigens. Progr. Liver Dis. 1993; 11: 251-67.
40. Alt M, Caselmann WH. Liver-directed gene therapy: Molecular tools and current preclinical and clinical studies. J. Hepatol. 1995; 23: 746-58.
41. Moradpour D, Compagnon B, Wilson BE, Nicolau C, Wands JR. Specific targeting of hepatocellular carcinoma cells by immunoliposomes in vivo. Hepatology 1995; 22: 1527-37.
42. Kanai F, Shiratori Y, Yoshida Y et al. Gene therapy for α-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the Herpes simplex virus thymidine kinase gene. Hepatology 1996; 23: 1359-68.
43. Hsu SL, Lin HM, Chou CK. Suppression of tumorigenicity of human hepatoma hep3B cells by long-term retinoic acid treatment. Cancer Lett. 1996; 99: 79-85.
44. Muto Y, Moriwaki H, Ninomiya M et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med. 1996; 334: 1561-7.
45. Yamamota M, Ogawa K, Morita M, Fukuda K, Komatsu Y. The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor β1. Hepatology 1996; 23: 552-9.
46. Bokemeyer C, Kynast B, Harstrick A et al. No synergistic activity of epirubicine and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1995; 35: 334-8.
47. Kawata A, Une Y, Hosokawa M et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am. J. Clin. Oncol. 1995; 18: 257-62.
48. Livraghi T, Bolondi L, Buscarini L et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: A retrospective analysis of survival in 391 patients with cirrhosis. J. Hepatol. 1995; 22: 522-6.
49. Soga K, Nomoto M, Ichida T, Aoyagi Y, Ozaki T, Ichida F. Clinical evaluation of transcatheter arterial embolization and one-shot chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 1988; 35: 116-20.
50. Toyoda H, Nakano S, Kumada T et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995; 52: 295-9.
51. Andersson M, Aronsen KF, Balch C et al. Pharmacokinetics of intra-arterial mitomycin C with or without degradable starch microsphere (DSM) in the treatment of non-resectable liver cancer. Acta Oncol. 1989; 28: 219-22.
52. Yen FS, Wu JC, Kuo BIT, Chiang JH, Chen TZ, Lee SD. Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. J. Gastroenterol. Hepatol. 1995; 10: 237-40.
53. Hsu HC, Wei TC, Tsang YM, Wu MZ, Lin YH, Chuang SM. Histological assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 1986; 57: 1184-91.
54. Lin DY, Liaw YF, Lee TY et al. Hepatic arterial embolization with unresectable hepatocellular carcinoma: A randomized clinical trial. Gastroenterology 1988; 94: 453-5.
55. Bronowicki JP, Vetter D, Dumas F et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: A study of 127 French patients. Cancer 1994; 74: 16-24.
56. Lin DY, Hung CF, Chen PC, Wu CS. Gastrointestinal bleeding after hepatic transcatheter arterial embolization in patients with hepatocellular carcinoma. Gastrointest. Endosc. 1996; 43: 132-7.
57. Bhattacharya S, Novell JR, Winslet MC, Hobbs KEF. Iodized oil in the treatment of hepatocellular carcinoma. Br. J. Surg. 1994; 81: 1563-71.
58. Mondazzi L, Bottelli R, Brambilia G et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors. Hepatology 1994; 19: 1115-23.
59. Stefanini GF, Amorati P, Biselli M et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75: 2427-34.
60. Goseki N, Nosaka T, Endo M, Koike M. Nourishment of hepatocellular carcinoma cells through the portal blood flow and without transcatheter arterial embolization. Cancer 1995; 76: 736-42.
61. Yamakado K, Hirano T, Kato N et al. Hepatocellular carcinoma: Treatment with a combination of transcatheter arterial chemoembolization and transportal ethanol injection. Radiology 1994; 193: 75-80.
62. Civalleri D, Pellicci R, Decaro G et al. Palliative chemoembolization of hepatocellular carcinoma with mitoxantrone, lipiodol, and gelfoam. A phase II study. Anticancer Res. 1996; 16: 937-41.
63. Ryder SD, Rizzi PM, Metivier E, Karani J, Williams R. Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma. Gut 1996; 38: 125-8.
64. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. Cancer 1994; 74: 2449-53.
65. Group d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med. 1995; 332: 1256-61.
66. Taguchi T. Chemo-occlusion for the treatment of liver cancer: A new technique using degradable starch microspheres. Clin. Pharmacokinet. 1994; 26: 275-91.
67. Kanai T, Monden M, Sakon M et al. New development of transcatheter immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother. Pharmacol. 1994; 33: S48-54.
68. Ito K, Kusunoki H, Okamoto E et al. Intra-arterial alcoholization of advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1994; 33: S42-7.
69. Wang SJ, Lin WY, Lui WY, Chen MN, Tsai ZT, Ting G. Hepatic artery injection of yttrium-90 lipiodol: Biodistribution in rats with hepatoma. J. Nucl. Med. 1996; 37: 332-5.
70. 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76: 2202-10.
71. Matsui O, Kadoya M, Yoshikawa J et al. Small hepatocellular carcinoma: Treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79-83.
72. Sheu JC, Huang GT, Chen DS et al. Small hepatocellular carcinoma: Intratumor ethanol treatment using new needle and guidance system. Radiology 1987; 163: 43-8.
73. Shiina S, Tagawa K, Unuma T et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer 1991; 68: 1524-30.
74. Ohnishi K, Ohyama N, Ito S, Fujiwara K. Small hepatocellular carcinoma: Treatment with US-guided intratumoral injection of acetic acid. Radiology 1994; 193: 747-52.
75. Ohnishi K, Nomura F, Ito S, Fujiwara K. Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: Study of 91 cases. Hepatology 1996; 23: 994-1002.
76. Honda N, Guo Q, Uchida H, Ohishi H, Hiasa Y. Percutaneous hot saline injection therapy for hepatic tumors: An alternative to percutaneous ethanol injection therapy. Radiology 1994; 190: 53-7.
77. Velti A, Martina C, Bonenti G et al. Treatment of malignant tumors using percutaneous hot saline injections. Feasibility study and preliminary results. Radiol. Med. 1995; 90: 463-9.
78. Livraghi T, Ravetto C, Solbiati L, Suter F. Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance. Tumori 1986; 72: 525-7.
79. Ha XF, Mack P, Elnatan J, Smith D, Porter AG, Goh CR. Response of rat Morris hepatoma to intra-tumoral administration of high dose recombinant human necrosis factor-β. J. Exp. Clin. Cancer Res. 1995; 14: 365-71.
80. Tian JH, Xu BX, Zhang JM, Dong BW, Liang P, Wang XD. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J. Nucl. Med. 1996; 37: 958-63.
81. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
82. Redvanly RD, Chezmar JL, Strauss RM, Galloway JR, Boyer TD, Bernardino ME. Malignant hepatic tumors: Safety of high-dose percutaneous ethanol ablation therapy. Radiology 1993; 188: 283-5.
83. Lai ECS, Choi TK, Tong SW, Ong GB, Wong J. Treatment of unresectable hepatocellular carcinoma: Results of a randomized controlled trial. World J. Surg. 1986; 10: 501-9.
84. Lawrence TS, Tesser RJ, Ten Haken RK. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1991; 20: 555-61.
85. Matsuzaki Y, Osuga T, Chiba T et al. New, effective treatment using proton irradiation for unresectable hepatocellular carcinoma. Int. Med. 1995; 34: 302-4.
86. Seki T, Wakabayashi M, Nakagawa T et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 74: 817-25.
87. Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takesukawa M, Sagara K. Treatment of hepatocellular carcinoma: Value of percutaneous microwave coagulation. AJR 1995; 164: 1159-64.
88. Sato M, Watanabe Y, Ueda S et al. Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 1996; 110: 1507-14.
89. Vogl T, Muller PK, Hammerstingl R et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: Technique and prospective results. Radiology 1995; 196: 257-65.
90. Rossi S, Fornari F, Buscarini L. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J. Intervent. Radiol. 1993; 8: 97-103.
91. Tanaka K, Nakamura S, Numata K et al. Hepatocellular carcinoma treatment with pure ethanol injection and transcatheter arterial embolization. Radiology 1992; 185: 457-60.
92. Bartolozzi C, Lencioni R, Caramella D et al, Treatment of large HCC: Transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197: 812-18.
93. 131I-labelled hepatoma-1 mAb: Preliminary results and discussion. Cancer Immunol. Immunother. 1994; 39: 332-6.
94. Himoto T, Watanabe S, Nishioka M, Maeba T, Tanaka S, Saito M. Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for hepatocellular carcinoma. Cancer Immunol. Immunother. 1996; 42: 127-31.
95. Ikeda K, Saito S, Koida I et al. A prospective randomized evaluation of a compound of Tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am. J. Clin. Oncol. 1995; 18: 204-10.
96. Curley SA. Update on regional treatment for hepatobiliary malignancies. Jpn. J. Cancer Chemother. 1995; 11: 1437-51.
97. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.